Greenbrook TMS — Investor Presentation (May 2021)
30 slides from Greenbrook TMS's investor presentation, May 5, 2021
Slide 1: Corporate Presentation
Corporate Presentation NASDAQ: GBNH TSX: GTMS This presentation is dated April 30 , 20 21 . A preliminary short form base PREP prospectus (“Canadian preliminary prospectus”) containing important information relating to the securities described in this presentation has been filed with the securities
Slide 2: Cautionary Note Regarding Forward-Looking Statements & Other Disclaimers
NASDAQ: GBNH, TSX: GTMS Cautionary Note Regarding Forward - Looking Statements & Other Disclaimers Some of the information contained in this presentation, including with respect to the expansion of our TMS Center network, the Spravato ® pilot program, or our Company’s future financial or operating p
Slide 3: Offering Summary
Offering Summary NASDAQ: GBNH, TSX: GTMS Issuer Greenbrook TMS Inc. Ticker / Exchange GBNH / NASDAQ, GTMS / TSX Offering 100% Primary Common Shares Underwriters’ Option 15% (100% Primary Common Shares) Use of Proceeds To develop new TMS centers, fund potential acquisitions, as well as working capita
Slide 4: Company at a Glance
NASDAQ: GBNH, TSX: GTMS TMS is eligible for reimbursement in all 50 states and from all major insurers TMS is an FDA - cleared, non - invasive therapy for the treatment of Major Depressive Disorder (MDD) in patients that have failed drug treatment and Obsessive Compulsive Disorder (OCD) Founded in 2
Slide 5: Key Investment Considerations
NASDAQ: GBNH, TSX: GTMS Key Investment Considerations FAST - GROWING LEADING PROVIDER FOR TMS TREATMENT IN U.S. • Proven organic and M&A growth strategy • ~50% annual revenue growth since 2015 • Targeting approximately 140 Centers by end of 1H 2021 SIGNIFICANT UNDERSERVED MARKET OPPORTUNITY • Curren
Slide 6: About Depression
About Depression About TMS Our Business Financial Performance Looking Forward 6
Slide 7: Adults diagnosed with MDD and treatment failure
17.3M Adults diagnosed with MDD 2 5.3M Fail to respond to drug therapy and could benefit from TMS treatment 2 Millions of MDD patients can potentially benefit from TMS NASDAQ: GBNH, TSX: GTMS Of treated MDD patients do not respond to the first round of treatment¹ 51% 1. Star*D Study (Note: 51% of MD
Slide 8: Treating Depression - TMS is a New Paradigm
Treating Depression - TMS is a New Paradigm NASDAQ: GBNH, TSX: GTMS Current First - Line Treatment When Drugs Fail - Neurostimulation Treatment Drugs can be highly effective but only 49% of the treated population benefit. Probability of successful treatment diminishes with each new drug tried or add
Slide 9: About TMS
About Depression About TMS Our Business Financial Performance Looking Forward 9
Slide 10: About TMS Therapy
About TMS Therapy NASDAQ: GBNH, TSX: GTMS TMS is an FDA - cleared neurostimulation therapy for MDD An alternative to ECT and a potential life - changing treatment option for MDD patients not responding to pharmaco - therapy and psychotherapy TMS therapy provides local electromagnetic stimulation to
Slide 11: About TMS Therapy
About TMS Therapy NASDAQ: GBNH, TSX: GTMS SHORT AND CONVENIENT TREATMENT • Administered in an office setting •19 - 38 minutes per treatment session • 36 treatment sessions, conducted over 4 - 6 week period • Typically 5 treatments per week • Post - TMS treatment, patients can immediately return to t
Slide 12: TMS – A Safe and Effective Alternative
TMS – A Safe and Effective Alternative 1. Star*D Study; 2.Journal of Clinical Psychiatry, 2014 Dec; 75(12); 3. Journal of Clinical Psychiatry, 2004 Apr; 65(4); Biol Ps ychiatry, 2004 Feb; 55(3). TREATMENT CLASS Medications TMS ECT/Shock Therapy 49% Response 28% Remission 1 62% Response 42% Remission
Slide 13: FDA Cleared TMS Treatment Systems
FDA Cleared TMS Treatment Systems NASDAQ: GBNH, TSX: GTMS There are 7 TMS devices currently cleared by FDA Current Greenbrook TMS device offerings 13
Slide 14: Insurance Coverage for TMS Treatment of MDD
Insurance Coverage for TMS Treatment of MDD NASDAQ: GBNH, TSX: GTMS TMS for MDD is now covered for over 300 MILLION lives in the U.S. TMS therapy is a potentially life - changing treatment for patients and provides a highly compelling value proposition to payers 2013 2014 2015 2016 2017 14
Slide 15: Our Business
About Depression About TMS Our Business Financial Performance Looking Forward 15
Slide 16: Key Opportunity/Growth Drivers
Greenbrook TMS - Key Opportunity/Growth Drivers NASDAQ: GBNH, TSX: GTMS Growing awareness / acceptance of depression and reduced stigma surrounding mental health issues broadly Growing acceptance of TMS as an effective second line therapy Safety and efficacy of TMS as a treatment option for patients
Slide 17: Greenbrook TMS Center Model – Patient Focused Service
Greenbrook TMS Center Model – Patient Focused Service NASDAQ: GBNH, TSX: GTMS Centralized, Scalable Business Infrastructure (IT, Billing, HR, Branding, Training, Regulatory, Finance) Patient Inquiry Direct to Consumer Marketing Professional Marketing Physician Referrals: Inbound and Outbound Call Ce
Slide 18: The Greenbrook TMS Experience
The Greenbrook TMS Experience NASDAQ: GBNH, TSX: GTMS PATIENT - FOCUS • TMS Centers are located in heavily - trafficked areas for ease of access, but discrete given the sensitive nature of depression CENTER AESTHETICS • Inviting atmosphere and attention to detail including selection of warm paint co
Slide 19: Current Footprint and Active Development Pipeline
Current Footprint and Active Development Pipeline NASDAQ: GBNH, TSX: GTMS Operating 128 TMS Centers spanning 15 U.S. states Current Footprint (128 TMS Centers) Virginia Maryland/Delaware North/South Carolina St. Louis Austin Houston Connecticut Cleveland Florida Michigan California Oregon Alaska OPE
Slide 20: Financial Performance
About Depression About TMS Our Business Financial Performance Looking Forward 20
Slide 21: Operational Performance
- 200 400 600 800 1,000 1,200 1,400 1,600 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 2012 2013 2014 2015 2016 2017 2018 2019 2020 Number of New Patient Starts - 10,000 20,000 30,000 40,000 50,000 60,000 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3
Slide 22: Financial Performance Summary – Revenue and Centers
Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 2018 2019 2020 Revenue 31 34 39 47 57 67 94 102 110 113 114 116 2 6 4 10 10 10 12 17 14 12 11 9 14 14 15 16 20 23 33 36 44 47 54 62 0 20 40 60 80 100 120 140 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 2018 2019 2020 TMS Centers Centers In-Development Active Centers Cente
Slide 23: Looking Forward
About Depression About TMS Our Business Financial Performance Looking Forward 23
Slide 24: Growth Strategy
Growth Strategy NASDAQ: GBNH, TSX: GTMS Four Key Drivers of Sustained Growth M&A • Opportunistic acquisitions of established centers • Fragmented market of many small groups • Well positioned for rapid integration New Regions • Foundation for growth recently established: - Florida - Michigan - Orego
Slide 25: Future Opportunities - New Indications
NASDAQ: GBNH, TSX: GTMS Future Opportunities - New Indications Greenbrook TMS is a service delivery platform, with an established and growing network of referring physicians. Our centers are well positioned to incorporate new treatment indications, if and when cleared by the FDA. TMS device manufact
Slide 26: What is Spravato?
NASDAQ: GBNH, TSX: GTMS What is Spravato ®? 26 In March 2019, the FDA approved Spravato ® nasal spray, in conjunction with an oral antidepressant, for treatment - resistant depression (“TRD”) in adults In August 2020, the FDA added a second indication for “depressive symptoms in adults with major de
Slide 27: Summary Capital Structure
Other Shareholders NASDAQ: GBNH, TSX: GTMS Greenbrook Summary Capital Structure Current Capitalization and Ownership Current Capitalization (1) Share Price ( March 31st, 2021 close) Common Shares O/S (mm) 13.7 Market Cap $158.2USD(GBNH) / $ 207.4 CAD(GTMS) Equity Capital Structure (mm) Basic Shares
Slide 28: Leadership Team
• Co - founder of Greenbrook TMS • 25 years experience as a healthcare executive • Co - founder, former Chairman and CEO of TLC Vision Corporation • Founder and Chairman of Greybrook Capital • Chairman of TearLab Leadership Team Erns Loubser CA CFA Chief Financial Officer Bill Leonard President & CE
Slide 29: Board of Directors
NASDAQ: GBNH, TSX: GTMS Board of Directors Elias Vamvakas Chairman Co - founder of Greenbrook TMS Co - founder, former Chairman and CEO of TLC Vision Corporation Founder and Chairman of Greybrook Capital President and CEO Co - founder of Greenbrook TMS Former President and CEO of Santen Inc. Directo
Slide 30: Thank You
Bill Leonard President & Chief Executive Officer Glen Akselrod Investor Relations glen@bristolir.com 905 - 326 - 1888 Thank You NASDAQ: GBNH, TSX: GTMS 30